Shopping Cart 0
Cart Subtotal
USD 0

Qiagen NV (QIA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Qiagen NV (Qiagen) is a provider of molecular testing solutions. The company offers consumable products, instruments and automation systems. The company's sample technologies help isolate and process DNA, RNA and proteins from samples such as blood and tissue; assay technologies to identify the genetic information of a pathogen in a tumor; bioinformatics solutions to analyze and interpret genomic data; and solutions to automate the use of consumables into efficient molecular testing workflows. It serves human healthcare, forensics, veterinary diagnostics, food safety testing, pharmaceutical and biotechnology and life sciences research markets. The company offers its products through subsidiaries and a network of independent distributors. It has operations in the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Qiagen is headquartered in Venlo, the Netherlands.

Qiagen NV (QIA)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 6

Qiagen NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Qiagen NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Qiagen NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Qiagen NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Qiagen NV, Medical Devices Deals, 2012 to YTD 2018 11

Qiagen NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Qiagen NV, Pharmaceuticals & Healthcare, Deal Details 15

Venture Financing 15

Numaferm Raises Additional Funds through Seed Financing 15

Protagen Raises USD12.5 Million in Venture Financing 16

Curetis Raises USD18 Million in Extended Series B Venture Financing 17

Private Equity 19

Sobera Capital And Triginta Capital Divest Stake In Biobase Through Management Buyout 19

Partnerships 20

Qiagen Enters Into Licensing Agreement With CeMM For Calreticulin Biomarker 20

Biobase Enters Into Licensing Agreement With University of Southern California And Children's Hospital of Philadelphia 21

Ingenuity Systems Enters Into Licensing Agreement With LabCorp For Clinical Content And Applications 22

Bristol-Myers Squibb and Qiagen Enter into Agreement 23

Qiagen Enters into Agreement with Genohm 24

Qiagen Enters into Agreement with Mirati Therapeutics 25

DNAnexus Enters into Partnership with Qiagen 26

Qiagen Enters into Agreement with GATC Biotech 27

Tokai Pharma Expands Agreement with Qiagen 28

Tokai Pharma Expands Agreement with Qiagen 29

Qiagen Enters into Agreement with ArcherDx 30

Protagen Enters into Agreement with Qiagen to Develop Novel Protein-Based Companion Diagnostics 31

AstraZeneca Enters into Co-Development Agreement with Qiagen 32

Qiagen Enters into Co-Development Agreement with Eli Lilly for Companion Diagnostic Test 33

Qiagen Forms Joint Venture With BioBay To Establish Translational Medicine Center 34

Ingenuity Systems Enters Into Co-Promotion Agreement With Affymetrix For Research Tools 35

Takara Bio Enters Into Co-Marketing Agreement With Exiqon For miRCURY LNA Products 36

ShanghaiBio Enters Into Agreement With Ingenuity Systems 37

Atlas Biolabs Enters Into Agreement With Ingenuity Systems 38

Convey Computer Enters Into Technology Integration Agreement With CLC bio 39

QIAGEN Enters Into Joint Venture Agreement With Bio-X Center 40

Labcyte Enters Into Technology Integration Agreement With QIAGEN 41

Licensing Agreements 42

Exiqon Enters into Licensing Agreement with Aarhus University Hospital 42

Inserm Transfert Enters into Licensing Agreement with HalioDx 43

Exiqon Enters into Licensing Agreement with Aarhus University Hospital 44

Qiagen Enters into Licensing Agreement with University of Tokyo for SF3B1 45

Sygnis Pharma Enters Into Licensing Agreement With Qiagen For Amplification Buffer 46

Transgenomic Expands Licensing Agreement with Exiqon 47

Roche Molecular Enters into Licensing Agreement with Qiagen 48

Helicos BioSciences Enters Into Licensing Agreement With Intelligent Bio-Systems For Single Molecule Sequencing Technology Patents 49

Genetrix Enters Into Licensing Agreement With Qiagen For Qualiphi 50

Equity Offering 51

Exiqon Completes Private Placement Of Shares For USD 2.6 Million 51

Debt Offering 52

Qiagen Raises USD400 Million in Private Placement of Notes 52

Exiqon Raises USD5.8 Million in Private Placement of 9.25% Note 53

Qiagen Completes Public Offering Of Senior Notes Due 2021 For USD 300 Million 54

Qiagen Completes Public Offering Of Senior Notes Due 2019 For USD 430 Million 55

Exiqon Completes Private Placement Of Bonds For USD 3 Million 56

Qiagen Raises USD300 Million in Private Placement of 3.75% Notes Due 2022 57

Qiagen Raises USD73 Million in Private Placement of 3.19% Notes Due 2019 58

Qiagen Raises USD27 Million in Private Placement of 3.9% Notes Due 2024 59

Acquisition 60

QIAGEN to Acquire Remaining 80.1% Stake in NeuMoDx Molecular for USD234 Million 60

Qiagen Acquires OmicSoft 61

Qiagen Acquires Exiqon for up to USD102.4 Million 62

Qiagen Acquires MO BIO Labs 64

Qiagen Acquires Enzymatics 65

Qiagen Acquires Biobase 66

Qiagen Acquires Ingenuity Systems 67

CLC bio Acquires Molegro, Developer Of Drug Discovery Software 68

Qiagen Acquires Intelligent Bio-Systems 69

Qiagen NV-Key Competitors 70

Qiagen NV-Key Employees 71

Qiagen NV-Locations And Subsidiaries 72

Head Office 72

Other Locations & Subsidiaries 72

Joint Venture 75

Recent Developments 76

Financial Announcements 76

Jul 31, 2018: QIAGEN Reports Results for Second Quarter and First Half of 2018 76

May 02, 2018: QIAGEN Announces First Quarter 2018 Financial Results 79

Jan 31, 2018: QIAGEN Reports Results for Fourth Quarter and Full-year 2017, Announces STAT-Dx Acquisition and New USD 200 Million Share Repurchase 81

Jul 27, 2017: QIAGEN Reports Results for Second Quarter and First Half of 2017 86

May 02, 2017: QIAGEN reports results for first quarter 2017 89

Feb 01, 2017: QIAGEN Reports Results for Fourth Quarter and Full-year 2016 91

Government and Public Interest 95

Aug 21, 2018: Mason researcher part of team awarded USD 2.5 million grant for investigating remedies to deadly virus 95

Appendix 96

Methodology 96

About GlobalData 96

Contact Us 96

Disclaimer 96


List Of Figure

List of Figures

Qiagen NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Qiagen NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Qiagen NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Qiagen NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Qiagen NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Qiagen NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Qiagen NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Qiagen NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Qiagen NV, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

Qiagen NV, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Qiagen NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Qiagen NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Qiagen NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Qiagen NV, Deals By Therapy Area, 2012 to YTD 2018 10

Qiagen NV, Medical Devices Deals, 2012 to YTD 2018 11

Qiagen NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Numaferm Raises Additional Funds through Seed Financing 15

Protagen Raises USD12.5 Million in Venture Financing 16

Curetis Raises USD18 Million in Extended Series B Venture Financing 17

Sobera Capital And Triginta Capital Divest Stake In Biobase Through Management Buyout 19

Qiagen Enters Into Licensing Agreement With CeMM For Calreticulin Biomarker 20

Biobase Enters Into Licensing Agreement With University of Southern California And Children's Hospital of Philadelphia 21

Ingenuity Systems Enters Into Licensing Agreement With LabCorp For Clinical Content And Applications 22

Bristol-Myers Squibb and Qiagen Enter into Agreement 23

Qiagen Enters into Agreement with Genohm 24

Qiagen Enters into Agreement with Mirati Therapeutics 25

DNAnexus Enters into Partnership with Qiagen 26

Qiagen Enters into Agreement with GATC Biotech 27

Tokai Pharma Expands Agreement with Qiagen 28

Tokai Pharma Expands Agreement with Qiagen 29

Qiagen Enters into Agreement with ArcherDx 30

Protagen Enters into Agreement with Qiagen to Develop Novel Protein-Based Companion Diagnostics 31

AstraZeneca Enters into Co-Development Agreement with Qiagen 32

Qiagen Enters into Co-Development Agreement with Eli Lilly for Companion Diagnostic Test 33

Qiagen Forms Joint Venture With BioBay To Establish Translational Medicine Center 34

Ingenuity Systems Enters Into Co-Promotion Agreement With Affymetrix For Research Tools 35

Takara Bio Enters Into Co-Marketing Agreement With Exiqon For miRCURY LNA Products 36

ShanghaiBio Enters Into Agreement With Ingenuity Systems 37

Atlas Biolabs Enters Into Agreement With Ingenuity Systems 38

Convey Computer Enters Into Technology Integration Agreement With CLC bio 39

QIAGEN Enters Into Joint Venture Agreement With Bio-X Center 40

Labcyte Enters Into Technology Integration Agreement With QIAGEN 41

Exiqon Enters into Licensing Agreement with Aarhus University Hospital 42

Inserm Transfert Enters into Licensing Agreement with HalioDx 43

Exiqon Enters into Licensing Agreement with Aarhus University Hospital 44

Qiagen Enters into Licensing Agreement with University of Tokyo for SF3B1 45

Sygnis Pharma Enters Into Licensing Agreement With Qiagen For Amplification Buffer 46

Transgenomic Expands Licensing Agreement with Exiqon 47

Roche Molecular Enters into Licensing Agreement with Qiagen 48

Helicos BioSciences Enters Into Licensing Agreement With Intelligent Bio-Systems For Single Molecule Sequencing Technology Patents 49

Genetrix Enters Into Licensing Agreement With Qiagen For Qualiphi 50

Exiqon Completes Private Placement Of Shares For USD 2.6 Million 51

Qiagen Raises USD400 Million in Private Placement of Notes 52

Exiqon Raises USD5.8 Million in Private Placement of 9.25% Note 53

Qiagen Completes Public Offering Of Senior Notes Due 2021 For USD 300 Million 54

Qiagen Completes Public Offering Of Senior Notes Due 2019 For USD 430 Million 55

Exiqon Completes Private Placement Of Bonds For USD 3 Million 56

Qiagen Raises USD300 Million in Private Placement of 3.75% Notes Due 2022 57

Qiagen Raises USD73 Million in Private Placement of 3.19% Notes Due 2019 58

Qiagen Raises USD27 Million in Private Placement of 3.9% Notes Due 2024 59

QIAGEN to Acquire Remaining 80.1% Stake in NeuMoDx Molecular for USD234 Million 60

Qiagen Acquires OmicSoft 61

Qiagen Acquires Exiqon for up to USD102.4 Million 62

Qiagen Acquires MO BIO Labs 64

Qiagen Acquires Enzymatics 65

Qiagen Acquires Biobase 66

Qiagen Acquires Ingenuity Systems 67

CLC bio Acquires Molegro, Developer Of Drug Discovery Software 68

Qiagen Acquires Intelligent Bio-Systems 69

Qiagen NV, Key Competitors 70

Qiagen NV, Key Employees 71

Qiagen NV, Subsidiaries 72

Qiagen NV, Joint Venture 75

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Qiagen NV, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Qiagen NV (Qiagen) is a provider of molecular testing solutions. The company offers consumable products, instruments and automation systems. The company's sample technologies help isolate and process DNA, RNA and proteins from samples such as blood and tissue; assay technologies to identify the genetic information of a pathogen in a tumor; bioinformatics solutions to analyze and interpret genomic data; and solutions to automate the use of consumables into efficient molecular testing workflows. It serves human healthcare, forensics, veterinary diagnostics, food safety testing, pharmaceutical and biotechnology and life sciences research markets. The company offers its products through subsidiaries and a network of independent distributors. It has operations in the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Qiagen is headquartered in Venlo, the Netherlands.

Qiagen NV (QIA)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 6

Qiagen NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Qiagen NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Qiagen NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Qiagen NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Qiagen NV, Medical Devices Deals, 2012 to YTD 2018 11

Qiagen NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Qiagen NV, Pharmaceuticals & Healthcare, Deal Details 15

Venture Financing 15

Numaferm Raises Additional Funds through Seed Financing 15

Protagen Raises USD12.5 Million in Venture Financing 16

Curetis Raises USD18 Million in Extended Series B Venture Financing 17

Private Equity 19

Sobera Capital And Triginta Capital Divest Stake In Biobase Through Management Buyout 19

Partnerships 20

Qiagen Enters Into Licensing Agreement With CeMM For Calreticulin Biomarker 20

Biobase Enters Into Licensing Agreement With University of Southern California And Children's Hospital of Philadelphia 21

Ingenuity Systems Enters Into Licensing Agreement With LabCorp For Clinical Content And Applications 22

Bristol-Myers Squibb and Qiagen Enter into Agreement 23

Qiagen Enters into Agreement with Genohm 24

Qiagen Enters into Agreement with Mirati Therapeutics 25

DNAnexus Enters into Partnership with Qiagen 26

Qiagen Enters into Agreement with GATC Biotech 27

Tokai Pharma Expands Agreement with Qiagen 28

Tokai Pharma Expands Agreement with Qiagen 29

Qiagen Enters into Agreement with ArcherDx 30

Protagen Enters into Agreement with Qiagen to Develop Novel Protein-Based Companion Diagnostics 31

AstraZeneca Enters into Co-Development Agreement with Qiagen 32

Qiagen Enters into Co-Development Agreement with Eli Lilly for Companion Diagnostic Test 33

Qiagen Forms Joint Venture With BioBay To Establish Translational Medicine Center 34

Ingenuity Systems Enters Into Co-Promotion Agreement With Affymetrix For Research Tools 35

Takara Bio Enters Into Co-Marketing Agreement With Exiqon For miRCURY LNA Products 36

ShanghaiBio Enters Into Agreement With Ingenuity Systems 37

Atlas Biolabs Enters Into Agreement With Ingenuity Systems 38

Convey Computer Enters Into Technology Integration Agreement With CLC bio 39

QIAGEN Enters Into Joint Venture Agreement With Bio-X Center 40

Labcyte Enters Into Technology Integration Agreement With QIAGEN 41

Licensing Agreements 42

Exiqon Enters into Licensing Agreement with Aarhus University Hospital 42

Inserm Transfert Enters into Licensing Agreement with HalioDx 43

Exiqon Enters into Licensing Agreement with Aarhus University Hospital 44

Qiagen Enters into Licensing Agreement with University of Tokyo for SF3B1 45

Sygnis Pharma Enters Into Licensing Agreement With Qiagen For Amplification Buffer 46

Transgenomic Expands Licensing Agreement with Exiqon 47

Roche Molecular Enters into Licensing Agreement with Qiagen 48

Helicos BioSciences Enters Into Licensing Agreement With Intelligent Bio-Systems For Single Molecule Sequencing Technology Patents 49

Genetrix Enters Into Licensing Agreement With Qiagen For Qualiphi 50

Equity Offering 51

Exiqon Completes Private Placement Of Shares For USD 2.6 Million 51

Debt Offering 52

Qiagen Raises USD400 Million in Private Placement of Notes 52

Exiqon Raises USD5.8 Million in Private Placement of 9.25% Note 53

Qiagen Completes Public Offering Of Senior Notes Due 2021 For USD 300 Million 54

Qiagen Completes Public Offering Of Senior Notes Due 2019 For USD 430 Million 55

Exiqon Completes Private Placement Of Bonds For USD 3 Million 56

Qiagen Raises USD300 Million in Private Placement of 3.75% Notes Due 2022 57

Qiagen Raises USD73 Million in Private Placement of 3.19% Notes Due 2019 58

Qiagen Raises USD27 Million in Private Placement of 3.9% Notes Due 2024 59

Acquisition 60

QIAGEN to Acquire Remaining 80.1% Stake in NeuMoDx Molecular for USD234 Million 60

Qiagen Acquires OmicSoft 61

Qiagen Acquires Exiqon for up to USD102.4 Million 62

Qiagen Acquires MO BIO Labs 64

Qiagen Acquires Enzymatics 65

Qiagen Acquires Biobase 66

Qiagen Acquires Ingenuity Systems 67

CLC bio Acquires Molegro, Developer Of Drug Discovery Software 68

Qiagen Acquires Intelligent Bio-Systems 69

Qiagen NV-Key Competitors 70

Qiagen NV-Key Employees 71

Qiagen NV-Locations And Subsidiaries 72

Head Office 72

Other Locations & Subsidiaries 72

Joint Venture 75

Recent Developments 76

Financial Announcements 76

Jul 31, 2018: QIAGEN Reports Results for Second Quarter and First Half of 2018 76

May 02, 2018: QIAGEN Announces First Quarter 2018 Financial Results 79

Jan 31, 2018: QIAGEN Reports Results for Fourth Quarter and Full-year 2017, Announces STAT-Dx Acquisition and New USD 200 Million Share Repurchase 81

Jul 27, 2017: QIAGEN Reports Results for Second Quarter and First Half of 2017 86

May 02, 2017: QIAGEN reports results for first quarter 2017 89

Feb 01, 2017: QIAGEN Reports Results for Fourth Quarter and Full-year 2016 91

Government and Public Interest 95

Aug 21, 2018: Mason researcher part of team awarded USD 2.5 million grant for investigating remedies to deadly virus 95

Appendix 96

Methodology 96

About GlobalData 96

Contact Us 96

Disclaimer 96


List Of Figure

List of Figures

Qiagen NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Qiagen NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Qiagen NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Qiagen NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Qiagen NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Qiagen NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Qiagen NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Qiagen NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Qiagen NV, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

Qiagen NV, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Qiagen NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Qiagen NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Qiagen NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Qiagen NV, Deals By Therapy Area, 2012 to YTD 2018 10

Qiagen NV, Medical Devices Deals, 2012 to YTD 2018 11

Qiagen NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Numaferm Raises Additional Funds through Seed Financing 15

Protagen Raises USD12.5 Million in Venture Financing 16

Curetis Raises USD18 Million in Extended Series B Venture Financing 17

Sobera Capital And Triginta Capital Divest Stake In Biobase Through Management Buyout 19

Qiagen Enters Into Licensing Agreement With CeMM For Calreticulin Biomarker 20

Biobase Enters Into Licensing Agreement With University of Southern California And Children's Hospital of Philadelphia 21

Ingenuity Systems Enters Into Licensing Agreement With LabCorp For Clinical Content And Applications 22

Bristol-Myers Squibb and Qiagen Enter into Agreement 23

Qiagen Enters into Agreement with Genohm 24

Qiagen Enters into Agreement with Mirati Therapeutics 25

DNAnexus Enters into Partnership with Qiagen 26

Qiagen Enters into Agreement with GATC Biotech 27

Tokai Pharma Expands Agreement with Qiagen 28

Tokai Pharma Expands Agreement with Qiagen 29

Qiagen Enters into Agreement with ArcherDx 30

Protagen Enters into Agreement with Qiagen to Develop Novel Protein-Based Companion Diagnostics 31

AstraZeneca Enters into Co-Development Agreement with Qiagen 32

Qiagen Enters into Co-Development Agreement with Eli Lilly for Companion Diagnostic Test 33

Qiagen Forms Joint Venture With BioBay To Establish Translational Medicine Center 34

Ingenuity Systems Enters Into Co-Promotion Agreement With Affymetrix For Research Tools 35

Takara Bio Enters Into Co-Marketing Agreement With Exiqon For miRCURY LNA Products 36

ShanghaiBio Enters Into Agreement With Ingenuity Systems 37

Atlas Biolabs Enters Into Agreement With Ingenuity Systems 38

Convey Computer Enters Into Technology Integration Agreement With CLC bio 39

QIAGEN Enters Into Joint Venture Agreement With Bio-X Center 40

Labcyte Enters Into Technology Integration Agreement With QIAGEN 41

Exiqon Enters into Licensing Agreement with Aarhus University Hospital 42

Inserm Transfert Enters into Licensing Agreement with HalioDx 43

Exiqon Enters into Licensing Agreement with Aarhus University Hospital 44

Qiagen Enters into Licensing Agreement with University of Tokyo for SF3B1 45

Sygnis Pharma Enters Into Licensing Agreement With Qiagen For Amplification Buffer 46

Transgenomic Expands Licensing Agreement with Exiqon 47

Roche Molecular Enters into Licensing Agreement with Qiagen 48

Helicos BioSciences Enters Into Licensing Agreement With Intelligent Bio-Systems For Single Molecule Sequencing Technology Patents 49

Genetrix Enters Into Licensing Agreement With Qiagen For Qualiphi 50

Exiqon Completes Private Placement Of Shares For USD 2.6 Million 51

Qiagen Raises USD400 Million in Private Placement of Notes 52

Exiqon Raises USD5.8 Million in Private Placement of 9.25% Note 53

Qiagen Completes Public Offering Of Senior Notes Due 2021 For USD 300 Million 54

Qiagen Completes Public Offering Of Senior Notes Due 2019 For USD 430 Million 55

Exiqon Completes Private Placement Of Bonds For USD 3 Million 56

Qiagen Raises USD300 Million in Private Placement of 3.75% Notes Due 2022 57

Qiagen Raises USD73 Million in Private Placement of 3.19% Notes Due 2019 58

Qiagen Raises USD27 Million in Private Placement of 3.9% Notes Due 2024 59

QIAGEN to Acquire Remaining 80.1% Stake in NeuMoDx Molecular for USD234 Million 60

Qiagen Acquires OmicSoft 61

Qiagen Acquires Exiqon for up to USD102.4 Million 62

Qiagen Acquires MO BIO Labs 64

Qiagen Acquires Enzymatics 65

Qiagen Acquires Biobase 66

Qiagen Acquires Ingenuity Systems 67

CLC bio Acquires Molegro, Developer Of Drug Discovery Software 68

Qiagen Acquires Intelligent Bio-Systems 69

Qiagen NV, Key Competitors 70

Qiagen NV, Key Employees 71

Qiagen NV, Subsidiaries 72

Qiagen NV, Joint Venture 75

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Qiagen NV, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.